Study of the Prognostic Impact of CD44 on Renal Cell Carcinoma

NCT06773377 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 77

Last updated 2025-01-14

No results posted yet for this study

Summary

1. Study the expression of CD44 in various histopathological types of RCC.
2. Study the association between CD44 expression and other clinicopathological parameters
3. study the impact of CD44 expressions in tumor and patients' survival

Conditions

  • Renal Cell Cancer

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-01
Primary Completion
2026-11-01
Completion
2026-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06773377 on ClinicalTrials.gov